Fidelity Investments’s Tourmaline Bio TRML Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q4 | – | Sell |
-1,451
| Closed | -$69.4K | – | 5591 |
|
|
2025
Q3 | $69.4K | Sell |
1,451
-55,986
| -97% | -$1.55M | ﹤0.01% | 3822 |
|
|
2025
Q2 | $918K | Sell |
57,437
-186,284
| -76% | -$3.02M | ﹤0.01% | 2749 |
|
|
2025
Q1 | $3.71M | Buy |
243,721
+208,234
| +587% | +$3.34M | ﹤0.01% | 2250 |
|
|
2024
Q4 | $720K | Buy |
35,487
+20,424
| +136% | +$514K | ﹤0.01% | 2784 |
|
|
2024
Q3 | $387K | Sell |
15,063
-221,665
| -94% | -$3.7M | ﹤0.01% | 2961 |
|
|
2024
Q2 | $3.04M | Sell |
236,728
-2,297
| -1% | -$37K | ﹤0.01% | 2229 |
|
|
2024
Q1 | $5.47M | Buy |
239,025
+133,136
| +126% | +$4.69M | ﹤0.01% | 2054 |
|
|
2023
Q4 | $2.77M | Buy |
105,889
+105,329
| +18,809% | +$2.11M | ﹤0.01% | 2230 |
|
|
2023
Q3 | $15.7K | Hold |
560
| – | – | ﹤0.01% | 3923 |
|
|
2023
Q2 | $17K | Buy |
560
+6
| +1% | +$153 | ﹤0.01% | 3933 |
|
|
2023
Q1 | $10.4K | Buy |
554
+437
| +374% | +$7.21K | ﹤0.01% | 4114 |
|
|
2022
Q4 | $1.19K | Buy |
117
+62
| +113% | +$996 | ﹤0.01% | 4617 |
|
|
2022
Q3 | $1K | Buy |
55
+43
| +358% | +$1.57K | ﹤0.01% | 4743 |
|
|
2022
Q2 | $1K | Sell |
12
-42
| -78% | -$3.31K | ﹤0.01% | 4806 |
|
|
2022
Q1 | $5K | Sell |
54
-216
| -80% | -$20.2K | ﹤0.01% | 4455 |
|
|
2021
Q4 | $41K | Sell |
270
-5,730
| -96% | -$848K | ﹤0.01% | 3285 |
|
|
2021
Q3 | $814K | Hold |
6,000
| – | – | ﹤0.01% | 2724 |
|
|
2021
Q2 | $881K | Buy |
+6,000
| New | +$919K | ﹤0.01% | 2688 |
|
Fidelity Investments's TRML Position: Q4 2025 in Review
Fidelity Investments sold out of Tourmaline Bio (TRML) in Q4 2025, closing a stake of 1,451 shares — an estimated $69.4K sold.
Fidelity Investments first reported a position in TRML in Q2 2021 and held it in 18 quarters. The position peaked at $5.47M in Q1 2024. 0 funds tracked by Wall St. Rank hold TRML as of Q4 2025.
- Fidelity Investments reported no remaining Tourmaline Bio position as of Q4 2025 after selling out during the quarter.
- Fidelity Investments sold 1,451 Tourmaline Bio shares in Q4 2025, an estimated $69.4K.
- Fidelity Investments first reported a position in Tourmaline Bio in Q2 2021 and held it in 18 quarters.
- Fidelity Investments's Tourmaline Bio position peaked at $5.47M in Q1 2024.
- 0 funds tracked by Wall St. Rank held Tourmaline Bio as of Q4 2025.
Based on Fidelity Investments's 13F filing for Q4 2025, filed 17 Feb 2026.